Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation.
- Author:
Seong Eun KIM
1
;
Suck Chei CHOI
;
Kyung Sik PARK
;
Moo In PARK
;
Jeong Eun SHIN
;
Tae Hee LEE
;
Kee Wook JUNG
;
Hoon Sup KOO
;
Seung Jae MYUNG
Author Information
- Publication Type:Original Article
- Keywords: Constipation; Microbiome; Probiotics
- MeSH: Bacteroides; Bifidobacterium; Constipation*; Feces; Humans; Lactobacillus; Microbiota; Probiotics*; Real-Time Polymerase Chain Reaction; Recurrence
- From:Journal of Neurogastroenterology and Motility 2015;21(1):111-120
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: We investigated gut flora characteristics in patients with functional constipation (FC) and influences of short-term treatment with VSL#3 probiotic on flora and symptom improvement. METHODS: Thirty patients fulfilling Rome III criteria for FC and 30 controls were enrolled. Fecal samples were obtained before and after VSL#3 intake (one sachet twice daily for 2 weeks) and flora were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Symptom changes were also investigated. RESULTS: The fold differences in Bifidobacterium and Bacteroides species were significantly lower in feces from FC, compared to in controls (P = 0.030 and P = 0.021). After taking VSL#3, the fold differences in Lactobacillus, Bifidobacterium and Bacteroides species increased in controls (P = 0.022, P = 0.018, and P = 0.076), but not in FC. Mean Bristol scores and complete spontaneous bowel movements (CSBMs)/week increased significantly in FC after ingesting VSL#3 (both P < 0.001). Relief of subjective CSBM frequency, stool consistency and abdominal bloating were reported in 70%, 60%, and 47% of patients. After VSL#3 cessation, 44.4% of patients with symptom improvement experienced constipation recurrence mostly within one month. CONCLUSIONS: Bifidobacterium and Bacteroides species might be quantitatively altered in FC. A short-term VSL#3 treatment can improve clinical symptoms of FC. Further studies are needed to investigate VSL#3's additional effects beyond altering gut flora to allevate constipation.
